The combination of amlodipine and angiotensin receptor blocker or diuretics in
high-risk hypertensive patients: rationale, design and baseline characteristics.
Author(s): Wang W(1), Ma L, Zhang Y, Deng Q, Liu M, Liu L.
Affiliation(s): Author information:
(1)Department of Evidence-Based Medicine, Cardiovascular Institute and Fuwai
Hospital, Beijing, PR China.
Publication date & source: 2011, J Hum Hypertens. , 25(4):271-7
The Chinese Hypertension Intervention Efficacy Study (CHIEF) is a multi-centre
randomized controlled clinical trial comparing the effects of
amlodipine+angiotensin II receptor blocker and amlodipine+diuretics on the
incidence of cardiovascular events, represented as a composite of non-fatal
stroke, non-fatal myocardial infarction and cardiovascular death events in
high-risk Chinese hypertensive patients. The study also evaluates the long-term
effects of lipid-lowering treatment and lifestyle modification. From October 2007
to October 2008, 13,542 patients were enrolled into the study in 180 centres in
China. Patients will be followed up for 4 years. There was no difference in
baseline characteristics between the two blood pressure arms.
|